Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: Association with extent of skin sclerosis and severity of pulmonary fibrosis

Journal of Rheumatology

Volumn 27, Issue 1, 2000, Pages 149-154

  Sato, Shinichi ^a   Nagaoka, Tetsuya ^a   Hasegawa, Minoru ^a   Tamatani, Takuya ^b   Nakanishi, Toru ^c   Takigawa, Masaharu ^c   Takehara, Kazuhiko ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^b JT Inc   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Connective tissue growth factor; Fibrosis; Systemic sclerosis; Transforming growth factor

Indexed keywords

ANTINUCLEAR ANTIBODY; CONNECTIVE TISSUE GROWTH FACTOR; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CHILD; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; POLYMYOSITIS; PRIORITY JOURNAL; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GROWTH SUBSTANCES; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MITOGENS; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 0033978653     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM. A strategy tor determining the pathogenesis of systemic sclerosis: is transforming growth factor ß the answer? Arthritis Rheum 1989;32:817-25.
2. Assoian RK, Fleurdelys BE, Stevenson HC, et al. Expression and secretion of type ß transforming growth factor by activated human macrophages. Proc Natl Acad Sci USA 1987;84:6020-4.
3. Kehrl JH, Wakefield LM, Roberts AB. et al. Production of transforming growth factor ß by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986;163:1037-50.
4. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor ß causes a persistent increase in steady-state amounts for type I and III collagen and fibronectin mRNAs in normal human dermal fibrohlasts. Biochem J 1987;247:597-604.
5. Raghow R, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Transforming growth factor-ß increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranslationally in cultured human dermal fibroblasts. J Clin Invest 1987;79:1285-8.
6. 2, with al (1) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 1990; 86:917-22.
7. Peltonen J, Kahäri L, Jaakkoia S, et al. Evaluation of transforming growth factor ß and type 1 procollagen gene expression in fibrotic skin disease by in situ hybridization. J Clin Invest 1990;94:365-71.
8. Gruschwitz M, Müller P, Sepp N, et al. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 1990;94:197-203.
9. Gabrielli A, DiLoreto C, Taborro R, et al. Immunohistochemical localization of intracellular and extracellular associated TGF-ß in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon. Clin Immunol Immunopathol 1993;68:340-9.
10. Stikakis PP, McCune BK, Tsokos M, et al. Immunohistological demonstration of transforming growth factor-ß isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 1993;69:199-204.
11. Higley H, Persichitte K, Chu S, et al. Immunocytochemical localisation and serologic detection of transforming growth factor ß1. Arthritis Rheum 1994;37:278-88.
12. Leof EB, Proper JA, Gouston AS. et al. Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor ß: a proposed model for indirect mitogenesis involving autocrine activity. Proc Natl Acad Sci USA 1986;83:2453-7.
13. Paulsson Y, Hummacher A, Heldin C-H, Westermark B. Possible positive autocrine feedback in the prereplicative phase of human fibroblasts. Nature 1987;328:715-7.
14. Soma Y, Grotendorst GR. TGF ß stimulates primary human skin fibroblast DNA synthesis via an autocrine production of PDGF-related peptides. J Cell Physiol 1989;140:246-53.
15. Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC induced immediate early gene product CEF-10. J Cell Biol 1991;114:1285-94.
16. Igarashi A, Okochi H, Bradham DM, Grotendorst GR. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 1993;4:637-45.
17. Tamatani T, Kobayashi H, Tezuka K, et al. Establishment of the enzyme-linked immunosorbent assay for connective tissue growth factor and its detection in the sera of biliary atresia. Biochem Biophys Res Commun 1998;251:748-52.
18. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996;107:404-11.
19. Grotendorst GR. Connective tissue growth factor: a mediator of TGF-ß action on fibroblasts. Cytokine Growth Factor Rev 1997;8:171-9.
20. Igarashi A, Nashiro K, Kikuchi K, et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995;105:280-4.
21. Subcommittee for Seleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
22. LeRoy EC, Krieg T, Black C, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
23. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
24. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Eng J Med 1975;292:403-7.
25. Steen VD, Powell DL, Medsger TAJ. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
26. Sato S, Ihn H, Soma Y, et al. Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum 1993;36:1137-41.
27. Igarashi A, Nashiro K, Kikuchi K, et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 1996;106:729-33.
28. Oemar BS, Werner A, Garnier J-M, et al. Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 1997;251:748-52.
29. Ito Y, Bende RJ, Oemar BS, et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998;53:853-61.
30. Kikuchi K, Kadono T, Ihn H, et al. Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-ß1. J Invest Dermatol 1995;105:128-32.
31. Shinozaki M, Kawara S, Hayashi N. et al. Induction of subcutaneous tissue fibrosis in newborn mice by transforming growth factor-ß -simultaneous application with basic fibroblast growth factor causes persistent fibrosis. Biochem Biophys Res Commun 1997;237:292-7.
32. Igarashi A, Nashiro K, Kikuchi K, et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995;105:280-4.
33. Mori T, Kawara S. Shinozaki M, et al. Role and interaction of connective tissue growth factor with transforming growth factor-ß in persistent fibrosis: a mouse fibrosis model. J Cell Physiol 1999;181:153-9.